Prothena Corporation plc (PRTA)
Last updated: 2026-10-21 06:06:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Prothena Corporation plc (PRTA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $8.50, with a market capitalization of $428.66M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.73 to $11.80. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$428.66M | |
$8.55 | |
$79.75 | |
$4.32 | |
$8.48 | |
443.51K | |
483.06K | |
-- | |
$11.80 | |
$7.73 | |
-- | |
-- |
Prothena Corporation plc (PRTA) Latest Closing Stock Price
Prothena Corporation plc (PRTA) last closed at $8.48 as of 2026-10-20 23:31:00, unchanged from the previous close of $8.48.
During the latest regular trading session, PRTA traded between $4.32 and $79.75, with a volume of 443.51K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Prothena Corporation plc (PRTA) 7-Day Stock Price Change
Over the past seven days, Prothena Corporation plc (PRTA) moved from $8.84 to $8.50, representing a decline of 3.80% ($0.34).
The stock traded between $8.19 and $9.31 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 572.07 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
PRTA 52-Week Price Position
Position in Range: 19.0%
PRTA is currently trading at $8.50, placing it 19.0% of the way from its 52-week low of $7.73 to its 52-week high of $11.80. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Prothena Corporation plc (PRTA)?
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
Prothena Corporation plc Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 67 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Prothena Corporation plc (PRTA) Stock on MEXC
Eligible investors can buy real shares of Prothena Corporation plc (PRTA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Prothena Corporation plc (PRTA) stock price today?
2.Is PRTA stock going up or down today?
3.What is PRTA pre-market price?
4.What is PRTA after-hours price?
5.Is PRTA stock trading now?
6.Where does PRTA sit relative to its 52-week high and low?
7.What sector is Prothena Corporation plc in?
8.What is Prothena Corporation plc's market capitalization and where is it listed?
9.How is PRTA valued in terms of P/E ratio and EPS?
10.Does Prothena Corporation plc pay a dividend?
Explore More US Stocks
Search Stocks
PRTA Stock Calculator
Estimate the value between PRTA shares and USD.
PRTA Shares to USD
1.00 PRTA shares = 8.504 USD
Calculations are estimates based on the latest available price and are for reference only.


